Stand Up to Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), raises medical research money through a nationally broadcast telethon and partnerships to establish formalized team science collaborations uniting the best basic scientists with the best clinicians to form "Dream Teams." We are proud to be one of the original five Dream Teams formed in 2009.
Our mission is to take our scientific and clinical observations and rapidly apply them to cutting edge clinical trials for patients diagnosed with breast cancer, ovarian cancer and endometrial cancer. Our Dream Team is composed of researchers and clinical investigators that have pioneered the discovery of the PI3K pathway and have proven its significance in women's cancers.
We are enrolling patients now in our breast cancer, ovarian cancer and endometrial clinical trials.
Clinical Trials - ENROLLING NOW
Breast Cancer and Ovarian Cancer - United States
"2-2-2" = two diseases - two drugs - two pharmaceutical companies. Featured in the Time Magazine cover story.
Phase I/II of BKM120.Olaparib for Triple Negative (Basal-like) Breast Cancer or High Grade Serous (Type 2) Ovarian Cancer
Breast Cancer - United States and Europe
A Trial of BKM120 (a PI3K inhibitor) in Patients with Triple Negative (Basal-like) Breast Cancer
Complete List of our Breast Cancer, Ovarian Cancer and Endometrial Cancer Clinical Trials.
The PI3K Dream Team in Women's Cancers represents an exceptional team science collaboration of Beth Israel Deaconess Medical Center (Boston, MA), MD Anderson Cancer Center (Houston, TX), Memorial Sloan-Kettering Cancer Center (New York, NY), Dana-Farber Cancer Institute (Boston, MA), Herbert Irving Comprehensive Cancer Center/Institute for Cancer Genetics - Columbia University (New York, NY), Vanderbilt-Ingram Cancer Center (Nashville, TN), Massachusetts General Hospital (Boston, MA ) and Vall d'Hebron Institute of Oncology (Barcelona, Spain)
2013 Stand Up to Cancer Scientific Summit (video)
, talk about the magazine's recent cover story, "How to Cure Cancer."
NBC Nightly News on the Breakthrough Prize (video)
Lewis C Cantley receives the 2013 Breakthrough Prize in Life Sciences.
by Andrea P. Myers, M.D., Ph.D.
State of the Fight: Cervical Cancer 2013
Andrea P. Myers, M.D., Ph.D., is a medical oncologist at the Dana-Farber
Cancer Institute, where she treats patients with advanced gynecologic
malignancies (ovarian, endometrial, cervical and vulvar cancers). Myers
is directing clinical trials that use PI3K pathway inhibitors in
gynecologic malignancies. (article
A combination of PI3-kinase and PARP inhibitors may be a treatment option for triple-negative breast cancer. Two studies about this research by PI3K Dream Team investigators were published in Cancer Discovery.
"Standing Up to Cancer" by Pam Zwemer
Posted on Huffington Post, the Internet Newspaper on September 4, 2012. A testimonial. (article).
"The New Backbone of Clinical Trial Design" by Douglas A. Levine, MD (MSKCC). (article)
Oncology Times article featuring a patient on one of our PI3k Dream Team's Clinical Trials. (article)
Watch Lew Cantley's appearance in a segment on 'Sugar' on 60 Minutes. There is a definite correlation between eating sugar that results in an insulin spike that can serve as a catalyst to fuel certain types of cancers. (video)
[Disclaimer: Please pardon the commercials that were embedded in the broadcast.]
Stand Up to Cancer Scientific Summit (video)
2012 SU2C SCIENTIFIC SUMMIT (photo)
A signature paper from our Stand Up to Cancer PI3K Team and chosen for evaluation by Faculty of 1000. (more)
SU2C's PI3K Pathway Dream Team (watch video)
Meet SU2C's Scientists: PI3K Dream Team
In the second of five in SU2C's Dream Team series, PI3K Team Leaders Cantley and Sawyers talk about the science behind their project focusing on women's cancers.
Team progress over the first nine months and looking ahead.
Special Series on Breakthroughs in Cancer
In Search of a Target, In Search of a Cure